The challenge of one billion adjuvanted vaccine doses: evaluating scalability, sustainability, and supply capacity of Quillaja saponin QS-21 for large-scale vaccine demand

The biomass of Quillaja saponaria is a well-characterized source of triterpenic saponins, a family of amphiphilic glycosides with broad industrial and biomedical relevance. Among these, the highly purified fraction QS-21, and the related fractions QHA and QHC, have strong immunostimulant properties and have become key adjuvant components of several FDA-approved human vaccines. The expanding global use of QS-21-based adjuvants has raised concerns regarding long-term availability and sustainability, as commercial production currently relies exclusively on extraction from Q. saponaria biomass sourced in Chile. This review summarizes the historical development, chemical features, and immunological relevance of QS-21, and critically evaluates existing and emerging production technologies in terms of a projected production benchmark of 50 Kg per year (corresponding to at least one billion 50 µg doses). We conclude that appropriate management of wild Quillaja forests can sustain kilogram-scale QS-21 purification, but to meet increasing demand, clonal plantation forestry will be the most practical and scalable strategy in the near future. Alternative approaches, including plant cell culture, engineered microorganisms, and chemical synthesis, remain scientifically promising but currently face technical and economic limitations for large-scale pharmaceutical production.